Share on StockTwits

Analysts at JPMorgan Chase & Co. hoisted their price objective on shares of Allergan (NYSE:AGN) from $115.00 to $130.00 in a research report issued to clients and investors on Wednesday, Analyst Ratings Net reports. JPMorgan Chase & Co.’s target price would suggest a potential upside of 5.00% from the stock’s previous close.

Shares of Allergan (NYSE:AGN) traded up 0.47% during mid-day trading on Wednesday, hitting $123.29. The stock had a trading volume of 924,082 shares. Allergan has a one year low of $81.33 and a one year high of $123.83. The stock’s 50-day moving average is $115.2 and its 200-day moving average is $97.95. The company has a market cap of $36.592 billion and a P/E ratio of 37.64.

Allergan (NYSE:AGN) last issued its quarterly earnings data on Tuesday, February 4th. The company reported $1.12 earnings per share for the quarter, missing the analysts’ consensus estimate of $1.34 by $0.22. The company had revenue of $1.66 million for the quarter, compared to the consensus estimate of $1.65 million. During the same quarter last year, the company posted $1.15 earnings per share. Allergan’s revenue was up 14.4% compared to the same quarter last year. On average, analysts predict that Allergan will post $5.46 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which is scheduled for Friday, March 21st. Stockholders of record on Friday, February 28th will be paid a dividend of $0.05 per share. This represents a $0.20 annualized dividend and a dividend yield of 0.16%. The ex-dividend date is Wednesday, February 26th.

Other equities research analysts have also recently issued reports about the stock. Analysts at Credit Suisse set a $140.00 price target on shares of Allergan in a research note on Tuesday. They now have an “outperform” rating on the stock. Separately, analysts at Argus raised their price target on shares of Allergan from $110.00 to $130.00 in a research note on Friday, February 7th. They now have a “buy” rating on the stock. Finally, analysts at Zacks reiterated an “outperform” rating on shares of Allergan in a research note on Thursday, February 6th. They now have a $138.00 price target on the stock. Six equities research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $119.48.

Allergan, Inc is a multi-specialty health care Company focused on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter products.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.